Sensei Biotherapeutics Announces Board Member Resignation and Consultant Role

2mon ago, source: TipRanks on MSN

Samuel Broder, MD has stepped down from his role on the Board of Directors at Sensei Biotherapeutics, Inc., where he served ...

Buy Rating Affirmed for Sensei Biotherapeutics on Strong Fiscal Health and Promising Clinical Trials

1mon ago, source: Business Insider

Sensei Biotherapeutics (SNSE) Company Description: Sensei Biotherapeutics Inc is a clinical-stage immunotherapy company. It is engaged in the discovery and development of next-generation therapies ...

Sensei Biotherapeutics to Participate in Canaccord Genuity’s Horizons in Oncology Virtual Conference

14d ago, source:

Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that Company management will participate ...

Sensei Biotherapeutics Inc (SNSE)

15d ago, source: Investing

Sensei Biotherapeutics, Inc. (SNSE) reported Q3 EPS of ($0.44), $0.04 worse than the analyst estimate of ($0.40).

Sensei Biotherapeutics Inc Ordinary Shares

6d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Sensei Biotherapeutics advances cancer therapy with new antibody

19d ago, source: Investing

BOSTON - Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), an immuno-oncology company, announced the publication of a paper in Nature Communications that details the development of a novel antibody ...

Post-J&J bid, Sensei explores new oncology VISTAs

28d ago, source: BioWorld

An increasingly popular target across varied cancer types is the immune system regulator V-domain Ig suppressor of T-cell activation (VISTA), where a number of developers have taken early stage aim – ...

Sensei Biotherapeutics CFO Erin Colgan to resign

21d ago, source: Investing

On Monday, Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a biopharmaceutical company, announced the upcoming resignation of Erin Colgan, the company's Chief Financial Officer (CFO). Ms. Colgan has ...

Sensei Biotherapeutics to Participate in Citi’s 2023 Virtual Oncology Leadership Summit

1mon ago, source: ADVFN

Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that Company ...

PLX Protalix BioTherapeutics, Inc.

15h ago, source: Seeking Alpha

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx ...

Sensei Biotherapeutics Inc Ordinary Shares

20d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Sensei Biotherapeutics advances cancer therapy with new antibody

19d ago, source: Investing

BOSTON - Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), an immuno-oncology company, announced the publication of a paper in Nature Communications that details the development of a novel antibody, SNS-101 ...